SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

NCT06835179 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Metastatic Colorectal Cancer
Microsatellite Stable (MSS) Colorectal Cancer (CRC)
RAS-mutant Colorectal Cancer

Interventions

RADIATION: SBRT
DRUG: PD-1 Inhibitors
DRUG: CapeOX + bevacizumab

Sponsor

The First Affiliated Hospital with Nanjing Medical University